ANSES proposes classifying resorcinol as an endocrine disruptor in the European CLP Regulation

Resorcinol is a substance used in the manufacture of tyres, rubber products, adhesives and industrial resins. It is also used in certain cosmetic and hygiene products (hair dyes, mascara for professional use), as an antioxidant in food products such as shrimp, and as an antiseptic in certain medicines.

In 2020, ECHA's Member State Committee (MSC) recognised that this substance met the definition of an endocrine disruptor . However, there was no consensus on identifying it as a substance of very high concern within the meaning of the REACH Regulation . The recent inclusion of endocrine disruption in the CLP Regulation provides another way of taking action, by proposing its classification as an endocrine disruptor for human health and giving regulatory recognition to its hazard properties.

A strengthened classification to protect human health

On the basis of its expert appraisal work, the Agency is proposing an extension* to the harmonised classification of resorcinol. In addition to the current classifications, it is recommending the following: Endocrine disruptor for human health, Category 1 (EUH380, may cause endocrine disruption in humans).

This classification means that it will be necessary to label resorcinol with appropriate warnings, hazard statements and precautionary statements, in accordance with the new rules of the CLP Regulation, to ensure that workers and consumers benefit from clear identification and communication on the presence of this hazard. (See box)

Classification proposal submitted for public consultation

The harmonised classification proposal for resorcinol has been submitted for public consultation on the ECHA website until 21 March 2025. The aim of this consultation is to give all stakeholders the opportunity to comment on these proposals, by providing any additional scientific arguments and information they may have. Comments can be sent via a dedicated form on the ECHA website.

Following this consultation stage, ANSES will respond to the comments received. The initial proposal, comments and ANSES's responses to them will be analysed by ECHA’s Committee for Risk Assessment, which will then issue its opinion on updating the classification of resorcinol.

Based on this opinion, the European Commission may, if appropriate, draft regulatory texts allowing the chosen classification to be included in the CLP Regulation.

* The compound currently has the following classifications:

- Acute toxicity (oral), Category 4 (H302, harmful if swallowed); 
- Specific target organ toxicity – Single exposure, Category 1 (H370, causes damage to organs – nervous system); 
- Skin irritation, Category 2 (H315, causes skin irritation); 
- Eye irritation, Category 2 (H319, causes serious eye irritation); 
- Skin sensitisation, Category 1 (H317, may cause an allergic skin reaction); 
-  Hazards for the aquatic environment – Acute hazard, Category 1 (H400, very toxic to aquatic life).